CTLA-4 is not constitutively expressed on effector T cells but is

CTLA-4 is not constitutively expressed on effector T cells but is rapidly induced upon TCR engagement.14 In patients with CHB, we found a greater propensity for the induction of CTLA-4 upon TCR stimulation with either mitogen or cognate peptide, with CTLA-4 induction in HBV-specific CD8 T cells correlating strongly with viral load. These data are in line with recent demonstrations that CTLA-4 plays a critical role in the effector T-cell compartment in addition to its contribution to regulatory T-cell function.15, 16 CTLA-4 mediated inhibition may depend

on the fact that it shares ligands (B7-1 and B7-2) with CD28 but has higher avidity; when the supply STI571 order of these ligands is limited, CTLA-4-mediated inhibitory signaling could override CD28-mediated positive costimulation.

In CHB, the ability of CTLA-4 to outcompete CD28 may be favored not only by the increase in CTLA-4, but also by the reduced levels of CD28 on CD8 T cells17 and by the scarcity of B7 selleck monoclonal antibody ligands on hepatocytes and other intrahepatic cells with antigen-presenting capability.18 We postulated that CTLA-4-mediated coinhibition may be one of the pathways that drives T cells encountering their antigen in the liver towards Bim-dependent apoptosis. In support of this, we found the highest intracellular levels of Bim in CTLA-4hi HBV-specific CD8 T cells. We speculate that CTLA-4 signaling may induce Bim by its capacity to reduce availability of IL-214 while increasing

cell-intrinsic transforming growth factor beta (TGF-β),19 which is up-regulated at the transcriptional level in HBV-specific CD8 T cells2 and can promote Bim-dependent attrition of LCMV-specific T cells.20 In most patients with CHB without evidence of liver inflammation, blocking the CTLA-4 receptor was able to reduce Bim expression. However, in patients with CHB-related liver inflammation the lack of reduction in Bim achieved by CTLA-4 blockade invoked a dominant role for other factors in driving this proapoptotic phenotype. We have recently described a signaling defect reducing cell-autonomous production of IL-2 in patients with CHB-related liver inflammation17 oxyclozanide that may limit the efficacy of CTLA-4 blockade in such patients. In addition, as discussed below, a number of different coinhibitory pathways may play nonredundant roles in T-cell exhaustion in CHB. To explore the therapeutic potential to reprogram the tolerogenic phenotype of HBV-specific CD8 T cells we examined the impact of antiviral therapy. A previous study of CD8 T-cell reconstitution on antiviral monotherapy had suggested that viral load reduction resulted in some increase in cytolytic responses against HLA-A2 restricted HBV epitopes,21 but that these were of limited lifespan.

Related posts:

  1. Anti-CD4 Antibodies cells were sufficiently triggered to up-regulate the effector sign CD44 antibody
  2. Consequently, numerous RAS effector pathways that regulate basic
  3. Caveolin one is expressed Inhibitors,Modulators,Libraries within
  4. Here, we show that scgn is expressed earlier than CB, CR or PV in
  5. Besides, MDA cells have wild sort PTEN when MDA cells don’t have
This entry was posted in Antibody. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>